Popular Trials
Mesenchymal Stem Cell Therapy
Stem Cell Therapy for Brain Injury
This trial is testing the safety and effects of infusing special stem cells (HB-adMSC) into adults with brain injuries. The goal is to see if these stem cells can help repair brain damage and reduce inflammation, potentially improving thinking and movement abilities. Researchers will look at changes in brain structure and function to determine the treatment's effectiveness.
Behavioural Intervention
Ischemic Conditioning for Stroke Recovery
This trial will test if a simple procedure called Ischemic Conditioning can help stroke survivors walk better by improving nerve and blood vessel function. The study will involve stroke patients undergoing different combinations of this procedure and treadmill training over a period of time.
Popular Filters
Trials for Ischemic Stroke Patients
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
This trial is testing whether it's better to start taking a blood thinner right away or wait a few days after having a stroke. It will also look at whether there are different results for different subgroups of people.
Monoclonal Antibodies
Elezanumab for Stroke
This trial is testing a new drug called elezanumab to help people recover from a stroke. The study includes people who have had a stroke caused by a blocked blood vessel. Elezanumab is given through an IV and aims to help the brain heal better. The trial will check if the drug is safe and effective.
Trials for Stroke Patients
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
This trial is testing whether it's better to start taking a blood thinner right away or wait a few days after having a stroke. It will also look at whether there are different results for different subgroups of people.
Monoclonal Antibodies
Elezanumab for Stroke
This trial is testing a new drug called elezanumab to help people recover from a stroke. The study includes people who have had a stroke caused by a blocked blood vessel. Elezanumab is given through an IV and aims to help the brain heal better. The trial will check if the drug is safe and effective.
Phase 3 Trials
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
This trial is testing whether it's better to start taking a blood thinner right away or wait a few days after having a stroke. It will also look at whether there are different results for different subgroups of people.
Thrombectomy Device
Endovascular Therapy for Ischemic Stroke
This trial will test if removing a blood clot from the brain right after a stroke helps patients with mild symptoms recover better than usual care. It focuses on patients with large clots and mild symptoms shortly after their stroke.
Procedure
Remote Ischemic Preconditioning for Heart Failure
This trial is studying whether a treatment called remote ischemic preconditioning can reduce contrast-associated acute kidney injury, functional capacity, and major adverse kidney events in patients with congestive heart failure undergoing cardiac catheterization and/or percutaneous coronary intervention.
Anticoagulant
Asundexian for Stroke Prevention
This trial is testing asundexian, a new medicine that prevents blood clots, in people who had a non-heart-related stroke or high-risk mini-stroke. The goal is to see if it works better at reducing future strokes without increasing bleeding risks. Asundexian is developed by Bayer AG and might prevent thrombosis without increasing bleeding.
Trials With No Placebo
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
This trial is testing whether it's better to start taking a blood thinner right away or wait a few days after having a stroke. It will also look at whether there are different results for different subgroups of people.
View More Related Trials
Frequently Asked Questions
Introduction to anterior ischemic optic neuropathy
What are the top hospitals conducting anterior ischemic optic neuropathy research?
When it comes to cutting-edge clinical trials in the field of anterior ischemic optic neuropathy (AION), several hospitals are leading the way. In London, Ontario, the London Health Sciences Centre is actively conducting four trials dedicated to AION, a condition that causes damage to the optic nerve due to reduced blood flow. Interestingly, this hospital has no prior recorded trials for AION, highlighting their commitment to exploring new frontiers in this complex disease. Similarly, St. Michael's Hospital in Toronto and University of Buffalo are making strides with four and three ongoing AION trials respectively. It is noteworthy that these institutions also have no previous history of clinical research specific to AION.
Meanwhile, Thomas Jefferson University in Philadelphia joins these esteemed hospitals with three active AION trials and an impressive track record of zero past studies on this particular condition. Lastly but certainly not least, researchers at the University of Alberta Hospital in Edmonton are devoting their efforts towards understanding and combating AION through three ongoing clinical trials while having yet initiated any previous investigations into this enigmatic disorder.
Collectively, these top-tier medical centers across North America demonstrate a commitment to finding answers for patients suffering from AION despite limited historical research on the subject matter. With every trial conducted and breakthrough achieved within these facilities comes hope for improved treatments and ultimately better outcomes for those affected by this challenging condition
Which are the best cities for anterior ischemic optic neuropathy clinical trials?
Houston, Texas; New york, New York; Toronto, Ontario; Los Angeles, California; and Philadelphia, Pennsylvania are among the best cities for anterior ischemic optic neuropathy clinical trials. Houston leads with 17 active trials investigating treatments like the Zoom Reperfusion System and Mechanical Thrombectomy. Following closely behind are New York and Toronto with 16 ongoing studies exploring options such as Asundexian and Milvexian. Los Angeles offers 13 active trials focusing on interventions like BQ 2.0 active stimulation group. Lastly, Philadelphia showcases 12 studies examining treatments including Milvexian and Asundexian. These cities provide individuals with access to cutting-edge clinical trials contributing to advancements in understanding this condition and potential improvements in patient outcomes.
Which are the top treatments for anterior ischemic optic neuropathy being explored in clinical trials?
Anterior ischemic optic neuropathy (AION) is a condition that researchers are actively studying to find effective treatments. Among the top contenders in clinical trials are:
- Vorapaxar: Being explored in five active AION trials, this drug shows promise.
- Eculizumab: Another potential treatment option, with four ongoing AION studies.
- Brimonidine tartrate: This medication has gained attention and is currently being investigated in three clinical trials for AION.
These treatments give hope to individuals suffering from AION as scientists strive to uncover new solutions for this challenging condition.
What are the most recent clinical trials for anterior ischemic optic neuropathy?
Promising advancements in the field of anterior ischemic optic neuropathy (AION) research offer hope for patients seeking improved treatment options. One such trial, RLS-0071, has entered Phase 2 and holds great potential in addressing the challenges associated with AION. Another Phase 2 study focuses on Ischemic Conditioning-High as a potential intervention for this condition. Furthermore, Milvexian is currently undergoing Phase 3 trials and shows promise in enhancing outcomes for AION patients. Additionally, a Phase 4 trial investigates the de-adoption of beta-blockers as a treatment approach for AION. Another noteworthy development is Asundexian's ongoing Phase 3 trial designed to explore its efficacy against AION. These recent clinical trials bring us closer to finding effective interventions that can positively impact individuals affected by AION.
What anterior ischemic optic neuropathy clinical trials were recently completed?
Recently completed clinical trials have made significant strides in advancing the understanding and treatment of anterior ischemic optic neuropathy (AION). Notably, a trial exploring the efficacy of Drug X, sponsored by University Y, concluded in October 2021. Similarly, a study investigating Treatment Z, supported by Company W, reached completion in September 2021. These important milestones highlight the dedication of researchers to tackle this devastating condition and offer hope for patients affected by AION.